mirage

Pegvisomant and cabergoline combination therapy in acromegaly

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Bernabeu, I. spa
dc.contributor.author Álvarez-Escolá, C. spa
dc.contributor.author Paniagua, A. E. spa
dc.contributor.author Lucas, T. spa
dc.contributor.author Pavón de Paz, María Isabel spa
dc.contributor.author Cabezas-Agrícola, J. M. spa
dc.contributor.author Casanueva, F. F. spa
dc.contributor.author Marazuela, M. spa
dc.date.accessioned 2013-11-27T17:25:50Z
dc.date.available 2013-11-27T17:25:50Z
dc.date.issued 2013 spa
dc.identifier.citation Bernabeu, I., Alvarez-Escolá, C., Paniagua, A. E., Lucas, T., Pavón-Paz, M. I., Cabezas-Agrícola, J. M., ..., & Marazuela, M. (2013). Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary, 16(1), 101-108. spa
dc.identifier.uri http://hdl.handle.net/11268/227
dc.description.abstract Combination with cabergoline may offer additional benefits to acromegalic patients on pegvisomant monotherapy. We evaluated the safety and efficacy profile of this combination and investigated the determinants of response. An observational, retrospective, cross-sectional study. Fourteen acromegalic patients (9 females), who were partially resistant to somatostatin analogs and on pegvisomant monotherapy. Cabergoline was added because of the presence of persistent mildly increased IGF-I. The mean follow-up time was 18.3 ± 10.4 months. The efficacy and safety profile was assessed. The influence of clinical and biochemical characteristics on treatment efficacy was studied. IGF-I levels returned to normal in 4 patients (28%) at the end of the study. In addition, some decline in IGF-I levels was observed in a further 5 patients. The % IGF-I decreased from 158 ± 64% to 124 ± 44% (p = 0.001). The average change in IGF-I was -18 ± 27% (range -67 to +24%). Lower baseline IGF-I (p = 0.007), female gender (p = 0.013), lower body weight (p = 0.031), and higher prolactin (PRL) levels (p = 0.007) were associated with a better response to combination therapy. There were no significant severe adverse events. Significant tumour shrinkage was observed in 1 patient. Combination therapy with pegvisomant and cabergoline could provide better control of IGF-I in some patients with acromegaly. Baseline IGF-I levels, female gender, body weight, and PRL levels affect the response to this combination therapy. spa
dc.language.iso eng spa
dc.title Pegvisomant and cabergoline combination therapy in acromegaly spa
dc.type article spa
dc.description.impact 2.222 JCR (2013) Q3, 75/123 Endocrinology & metabolism spa
dc.identifier.doi 10.1007/s11102-012-0382-z spa
dc.rights.accessRights closedAccess en
dc.subject.unesco Endocrinología spa
dc.subject.unesco Tratamiento médico spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record